Study 
diagnosis by biopsy. Two incorrect randomisations in each group. Patient characteristics similar in the two groups and ali under care of one surgical team.
Interventions-Mastectomy group received wedge mastectomy plus excision of symptomatic axillary lymph nodes. Tamoxifen group received continuous treatment with tamoxifen 20 mg twice daily. Patients in tamoxifen group received wedge mastectomy if there was sign of local progression. Those in mastectomy group received further excision or radiotherapy for locoregional recurrence and when local treatments had been exhausted or metastatic disease diagnosed they received tamoxifen.
End point-Treatment efficacy was assessed by local control of disease and by survival.
Main results-Mortality from metastatic cancer in tamoxifen group was 7 (10.6%) and in mastectomy group 10 (15.3%) (NS). There was no difference in survival between the two groups. In mastectomy group 70% remained alive and free of local recurrence at 24 months; in tamoxifen group only 47% remained alive and free of local progression. In mastectomy group locoregional recurrence occurred in 16 patients and metastatic disease in 13; in tamoxifen group locoregional progression occurred in 29 patients and metastatic disease in seven.
Introduction
The Patients and methods During 1982-7 elderly patients who had operable breast cancer were entered into a prospective randomised study that compared wedge mastectomy with tamoxifen as a primary treatment. Breast cancer was diagnosed histologically from trucut biopsy samples. The criteria for entering patients into this study were that they had operable breast cancer (maximum diameter of tumour <5 cm); that they were aged >70 years; and that they were assessed as being fit for either treatment at the time of entry into the study.
Patients who were judged to fulfil these criteria were randomised to receive either tamoxifen 20 
The log rank test was used to calculate survival from the date of initial treatment. When other statistical tests were used these are clearly indicated.
Results Table II shows the response rate to tamoxifen as initial treatment. There was no operative mortality in the group who had a wedge mastectomy. There was no difference in survival between patients treated initially with tamoxifen and those treated by wedge mastectomy, though the 95% confidence intervals were wide, especially over the later years in the study (fig 2) .
There was no significant difference between the number of deaths in the wedge mastectomy group (17) and that in the tamoxifen group (10) (X2=2-42, 1 df, p>005). Table III 7 6 4 No ef Grade There were further disadvantages in using tamoxifen as initial treatment-namely, patients who are receiving tamoxifen and in whom the disease is responding or remaining static require indefinite treatment with regular assessment, and on progression the patient may not be fit for surgery or the tumour may be inoperable, as in two of our patients. By contrast, no patient who received wedge mastectomy and who had recurrent disease was unfit to receive tamoxifen. The rate of local or regional recurrence, or both, after wedge mastectomy at a mean follow up of 25 months was 24%, comprising 4% local recurrence only, 11% regional recurrence only, and 9% local and regional recurrence. The Cancer Research Campaign (Kings/Cambridge) trial for early breast cancer reported corresponding recurrence rates after simple mastectomy alone of 16% at 24 months and 26% at 48 months.5 In patients aged under 70 treated by simple mastectomy in our unit the rate of local or regional recurrence, or both, at 48 months was 24%,6 comprising 12% local recurrence only, 7% regional recurrence only, and 5% local and regional recurrence. The increased rate of recurrence in our wedge mastectomy group compared with that seen after simple mastectomy is due mainly to more regional recurrence rather than local recurrence. This might have been expected, as lymph nodes were excised at the time of wedge mastectomy only if they were symptomatic. Elderly patients who have palpable glands at the time of wedge mastectomy should perhaps have these excised at that time. Wedge mastectomy does not seem to result in an increased rate of local recurrence yet retains the advantages ofrapidity and reduced morbidity compared with simple mastectomy.
The number of deaths and the causes were similar in each treatment group; the number of deaths due to metastatic disease were again similar in both groups. There was no significant difference between the two groups in the time until metastatic disease occurred or in survival once metastatic disease was diagnosed, though the numbers were small and confidence intervals wide. The grade of the tumour was a significant factor that affected both the disease free interval and survival in the wedge mastectomy group; similar data from a Nottingham study of a much larger group of patients, who were aged less than 70 years and had operable breast cancer, showed similar correlations.4 In a prospective study multivariate analysis has confirmed grade as being the most important prognostic factor in operable disease in patients aged less than 70 years.7 Of 23 patients treated initially with tamoxifen and in whom the grade of tumour was assessed from a mastectomy specimen after local progression, 15 (65%) had grade 3 tumours. This compared with 42% of the patients treated initially by mastectomy who had grade 3 tumours. More grade 3 tumours seem to progress during tamoxifen treatment than grade 1 and grade 2 tumours. The results of this study confirm the importance of the grade of the primary tumour, even in elderly patients.
Previous studies have shown a high incidence of tumours rich in oestrogen receptors in elderly patients.' In patients who have locally advanced breast cancer tamoxifen has a reported response rate of 44%.8
The high response rate (>60%) to tamoxifen in elderly patients who have operable disease may be due to the high concentration of oestrogen receptors, though other factors such as the size of the tumour must also be considered: in this series patients who had small tumours treated initially with tamoxifen seem to have fared better than patients who had large tumours. This may support the use of adjuvant hormone treatment.
As yet, there is no single factor that can be used to predict accurately which tumours might be well controlled by tamoxifen for long periods, though further investigation of factors such as size, grade, and oestrogen receptor state taken together might identify a subgroup of patients in whom tamoxifen would give good local control.
Tamoxifen seems to be an alternative primary treatment for elderly patients who have breast cancer, in that survival is not significantly different from that of patients treated by wedge mastectomy. Surgery, however, has advantages over tamoxifen as an initial treatment, as wedge mastectomy controls primary disease in more patients, and on recurrence of local disease patients treated by wedge mastectomy are always fit to take tamoxifen, irrespective of the state of the patient or disease. Furthermore, tamoxifen has no advantage over wedge mastectomy in respect of the time until systemic recurrence. We believe that in elderly patients who have operable breast cancer mastectomy is the initial treatment of choice if they are fit for surgery. In elderly patients who are unfit for surgery, however, tamoxifen seems to be the most appropriate first line treatment. Small, well differentiated tumours fared better than larger grade 3 tumours.
This study supports the findings of Herbsmen et al that survival in older and younger patients who have breast cancer is comparable9 and also the conclusions of Donegan that breast cancer in the elderly is no less malignant than in younger women and that optimum treatment is indicated in all patients irrespective of age.'0 Because most of the group treated with tamoxifen ultimately required mastectomy we believe that the treatment of elderly patients who have operable breast cancer should include mastectomy. The optimum treatment may include both mastectomy and tamoxifen. The same ebb and flow of the tide of temperance is still witnessed. As the whirlwind of revolution clears the air and prepares the way fot the advance of truth, all these revivals and missions have directed the attention of the thoughtful to the study of the whole subject. The voice of science is beginning to teach that inebriety is a disease, and must be treated accordingly. Four medical societies and one quarterly journal are devoted exclusively to the study of the laws which govern inebriety. This increasing recognition of the disease aspect of intemperance is only the re-affirmation of a truth urged centuries ago, but the times were not then propitious for its reception and growth.
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